Specifically, RBM3 expression may aid in refining risk stratification models and guide prognostic assessment in patients with histologically favorable or early-stage epithelial ovarian cancer, particularly where advanced molecular testing is not readily available. This evidence concerns the gene RBM3 and ovarian carcinoma.